825 related articles for article (PubMed ID: 27585394)
1. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Lambert JA; Raju SV; Tang LP; McNicholas CM; Li Y; Courville CA; Farris RF; Coricor GE; Smoot LH; Mazur MM; Dransfield MT; Bolger GB; Rowe SM
Am J Respir Cell Mol Biol; 2014 Mar; 50(3):549-58. PubMed ID: 24106801
[TBL] [Abstract][Full Text] [Related]
3. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.
Sloane PA; Shastry S; Wilhelm A; Courville C; Tang LP; Backer K; Levin E; Raju SV; Li Y; Mazur M; Byan-Parker S; Grizzle W; Sorscher EJ; Dransfield MT; Rowe SM
PLoS One; 2012; 7(6):e39809. PubMed ID: 22768130
[TBL] [Abstract][Full Text] [Related]
4. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast partially reverses smoke-induced mucociliary dysfunction.
Schmid A; Baumlin N; Ivonnet P; Dennis JS; Campos M; Krick S; Salathe M
Respir Res; 2015 Oct; 16():135. PubMed ID: 26521141
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
7. Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa-induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epithelia.
Cho DY; Zhang S; Skinner DF; Lim DJ; Banks C; Grayson JW; Tearney GJ; Rowe SM; Woodworth BA
Int Forum Allergy Rhinol; 2022 May; 12(5):690-698. PubMed ID: 34704673
[TBL] [Abstract][Full Text] [Related]
8. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.
Woodworth BA
Laryngoscope; 2015 Oct; 125 Suppl 7(0 7):S1-S13. PubMed ID: 25946147
[TBL] [Abstract][Full Text] [Related]
10. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
[TBL] [Abstract][Full Text] [Related]
11. Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.
Lin VY; Fain MD; Jackson PL; Berryhill TF; Wilson LS; Mazur M; Barnes SJ; Blalock JE; Raju SV; Rowe SM
Am J Respir Cell Mol Biol; 2019 Aug; 61(2):162-173. PubMed ID: 30576219
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
Wang Y; Cai Z; Gosling M; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
[TBL] [Abstract][Full Text] [Related]
13. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis transmembrane conductance regulator modulation by the tobacco smoke toxin acrolein.
Alexander NS; Blount A; Zhang S; Skinner D; Hicks SB; Chestnut M; Kebbel FA; Sorscher EJ; Woodworth BA
Laryngoscope; 2012 Jun; 122(6):1193-7. PubMed ID: 22522920
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.
Birket SE; Chu KK; Houser GH; Liu L; Fernandez CM; Solomon GM; Lin V; Shastry S; Mazur M; Sloane PA; Hanes J; Grizzle WE; Sorscher EJ; Tearney GJ; Rowe SM
Am J Physiol Lung Cell Mol Physiol; 2016 May; 310(10):L928-39. PubMed ID: 26968770
[TBL] [Abstract][Full Text] [Related]
16. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
[TBL] [Abstract][Full Text] [Related]
17. Assessment of acquired mucociliary clearance defects using micro-optical coherence tomography.
Tipirneni KE; Grayson JW; Zhang S; Cho DY; Skinner DF; Lim DJ; Mackey C; Tearney GJ; Rowe SM; Woodworth BA
Int Forum Allergy Rhinol; 2017 Sep; 7(9):920-925. PubMed ID: 28658531
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
19. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
